The biotech playbook often reads like a study in delayed gratification, and Replimune Group just authored its own chapter. After absorbing two Complete Response Letters and a skeptical staff review from the FDA, the company secured accelerated approval on Thursday for Tudriqev (vusolimogene oderparepvec, formerly RP1) — an oncolytic virus therapy paired with Bristol Myers Squibb’s Opdivo for adults with unresectable, advanced melanoma that has progressed on anti-PD-1 treatment.
The approval marks a first: no oncolytic virus has previously been cleared in combination with a checkpoint inhibitor. It also ends a ten-year drought for the class, with the FDA having last approved an oncolytic viral therapy in 2015 when Amgen’s Imlygic reached the market — a product that never gained meaningful commercial traction.
A Bruising Path to Green Light
The regulatory journey was anything but smooth. Replimune had already weathered two Complete Response Letters before the FDA’s advisory committee for cell, tissue, and gene therapies voted 10-3 on July 30 that the efficacy data from the IGNYTE study were reliable and clinically meaningful — a vote that came despite a negative staff review ahead of the meeting.
The approval rests on data from 91 evaluable patients out of 140 enrolled in the IGNYTE trial. The combination of Tudriqev and Opdivo delivered an objective response rate of 24.2 percent, with a median duration of response of 14.1 months. Modest on the surface, those figures proved sufficient for the agency in the context of heavily pretreated melanoma patients.
That conditional clearance, however, carries a string attached. The therapy’s long-term fate hinges on the confirmatory Phase 3 IGNYTE-3 trial, which randomizes roughly 400 patients and uses overall survival as its primary endpoint. Management indicates the study is about one-third enrolled, with topline data expected no earlier than late 2027 — possibly slipping to 2030. Investors are therefore buying not just an approved product, but a bet on a distant, unresolved data point.
Pricing for a Competitive Landscape
Replimune has positioned Tudriqev at a list price of $450,000 per therapy course before typical discounts — undercutting Iovance Biotherapeutics’ Amtagvi, the only other approved option for this patient population, which lists at $562,000. Amtagvi, approved in 2024, generated $91 million in US sales in the second quarter, up 40 percent, signaling real market demand.
The rollout strategy is deliberately measured. Replimune plans to supply 200 early-adopter centers within the first six months, expanding to 450 centers after nine to twelve months, and eventually up to 1,200 — which would represent roughly 30 percent of the approximately 10,000 melanoma patients treated annually in the US. CFO Emily Hill said the company expects commercial launch within about 60 days.
Should investors sell immediately? Or is it worth buying Replimune?
Wall Street’s Verdict Arrives in Waves
Analysts have responded with a flurry of target price revisions. Wedbush upgraded the stock from Neutral to Outperform on Friday, lifting its target from $12 to $19. BMO Capital raised its target the same day from $16 to $20. JPMorgan Chase had already bumped its target from $17 to $20 on Thursday while maintaining an Overweight rating. Leerink had upgraded from Market Perform to Outperform on Tuesday, moving its target from $11 to $17. Piper Sandler had jumped ahead of the curve in late July, upgrading from Hold to Strong Buy immediately after the advisory committee’s positive vote.
The revenue forecasts diverge considerably. Leerink Partners analyst Daina Graybosch pegged potential peak sales at $618 million on August 3, while the Wall Street consensus hovers around $1 billion. BMO Capital went further, modeling peak sales of $1.3 billion by 2035, citing the broad label and limited FDA restrictions.
Institutional Support and Lingering Risks
The approval has drawn institutional money. State Street Corporation disclosed a 5.3 percent passive stake in a regulatory filing, while Focus Partners Advisor Solutions and the state of Wyoming built new positions according to 13F filings — evidence that professional investors are warming to a name long weighed down by regulatory uncertainty.
Not everything is rosy. Two US law firms have reminded investors of an early October deadline to join a securities class action alleging misleading statements between October 2025 and April 2026. The company’s balance sheet, however, offers near-term comfort: Replimune ended its fiscal year with $268.9 million in cash, which management projects will fund operations into the first quarter of calendar 2027.
A Stock Priced for What Comes Next
The market’s response has been measured rather than euphoric. The stock closed Friday at €10.44 in German trading, nearly flat on the day but up 7.58 percent for the week, putting the market capitalization at roughly €876.5 million. The annualized volatility above 335 percent underscores how quickly sentiment can shift in either direction with each new data point.
The approval has resolved one question — whether Tudriqev would reach patients — but the more consequential ones about commercial reach and confirmatory trial results remain open. With the launch now weeks away, the market will soon have real-world evidence to weigh against the promise.
Ad
Replimune Stock: Buy or Sell?! New Replimune Analysis from August 9 delivers the answer:
The latest Replimune figures speak for themselves: Urgent action needed for Replimune investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 9.
Replimune: Buy or sell? Read more here...
